English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene

Goel, A., Carlson, S., Classic, K., Greiner, S., Power, A., Bell, J., et al. (2007). Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood, 110(7), 2342-2350. doi:10.1182/blood-2007-01-065573.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0013-CB81-7 Version Permalink: http://hdl.handle.net/21.11116/0000-0003-BB8B-E
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Goel, AI, Author
Carlson, SK, Author
Classic, KL, Author
Greiner, S, Author
Power, AT1, Author              
Bell, JC, Author
Russell, SJ, Author
Affiliations:
1External Organizations, ou_persistent22              

Content

show
hide
Free keywords: -
 Abstract: Multiple myeloma is a radiosensitive malignancy that is currently incurable. Here, we generated a novel recombinant vesicular stomatitis virus [VSV(Δ51)-NIS] that has a deletion of methionine 51 in the matrix protein and expresses the human sodium iodide symporter (NIS) gene. VSV(Δ51)-NIS showed specific oncolytic activity against myeloma cell lines and primary myeloma cells and was able to replicate to high titers in myeloma cells in vitro. Iodide uptake assays showed accumulation of radioactive iodide in VSV(Δ51)-NIS–infected myeloma cells that was specific to the function of the NIS transgene. In bg/nd/xid mice with established subcutaneous myeloma tumors, administration of VSV(Δ51)-NIS resulted in high intratumoral virus replication and tumor regression. VSV-associated neurotoxicity was not observed. Intratumoral spread of the infection was monitored noninvasively by serial gamma camera imaging of 123I-iodide biodistribution. Dosimetry calculations based on these images pointed to the feasibility of combination radiovirotherapy with VSV(Δ51)-NIS plus 131I. Immunocompetent mice with syngeneic 5TGM1 myeloma tumors (either subcutaneous or orthotopic) showed significant enhancements of tumor regression and survival when VSV(Δ51)-NIS was combined with 131I. These results show that VSV(Δ51)-NIS is a safe oncolytic agent with significant therapeutic potential in multiple myeloma.

Details

show
hide
Language(s):
 Dates: 2007-10
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: DOI: 10.1182/blood-2007-01-065573
BibTex Citekey: GoelCCGPBR2007
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Blood
  Other : Blood
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Philadelphia, Pa. : W.B. Saunders
Pages: - Volume / Issue: 110 (7) Sequence Number: - Start / End Page: 2342 - 2350 Identifier: ISSN: 0006-4971
CoNE: https://pure.mpg.de/cone/journals/resource/954925385125